Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Common Equity (2016 - 2026)

Iradimed has reported Common Equity over the past 14 years, most recently at $98.5 million for Q1 2026.

  • Quarterly Common Equity rose 9.39% to $98.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $98.5 million through Mar 2026, up 9.39% year-over-year, with the annual reading at $94.6 million for FY2025, 8.98% up from the prior year.
  • Common Equity was $98.5 million for Q1 2026 at Iradimed, up from $94.6 million in the prior quarter.
  • Over five years, Common Equity peaked at $98.5 million in Q1 2026 and troughed at $62.5 million in Q1 2022.
  • The 5-year median for Common Equity is $76.1 million (2024), against an average of $79.6 million.
  • Year-over-year, Common Equity fell 3.06% in 2023 and then increased 21.56% in 2024.
  • A 5-year view of Common Equity shows it stood at $73.7 million in 2022, then fell by 3.06% to $71.4 million in 2023, then rose by 21.56% to $86.8 million in 2024, then grew by 8.98% to $94.6 million in 2025, then increased by 4.12% to $98.5 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Common Equity are $98.5 million (Q1 2026), $94.6 million (Q4 2025), and $98.4 million (Q3 2025).